Cargando…
PRP4K is a HER2-regulated modifier of taxane sensitivity
The taxanes are used alone or in combination with anthracyclines or platinum drugs to treat breast and ovarian cancer, respectively. Taxanes target microtubules in cancer cells and modifiers of taxane sensitivity have been identified in vitro, including drug efflux and mitotic checkpoint proteins. H...
Autores principales: | Corkery, Dale P, Le Page, Cécile, Meunier, Liliane, Provencher, Diane, Mes-Masson, Anne-Marie, Dellaire, Graham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612451/ https://www.ncbi.nlm.nih.gov/pubmed/25602630 http://dx.doi.org/10.1080/15384101.2015.1007775 |
Ejemplares similares
-
Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking
por: Corkery, D P, et al.
Publicado: (2018) -
A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma
por: Le Page, Cécile, et al.
Publicado: (2019) -
BMP-2 signaling in ovarian cancer and its association with poor prognosis
por: Le Page, Cécile, et al.
Publicado: (2009) -
Tinker, Tailor, Tumour Suppressor: The Many Functions of PRP4K
por: Habib, Elias B., et al.
Publicado: (2022) -
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
por: Le Page, Cécile, et al.
Publicado: (2010)